- AU$48.77m
- AU$43.37m
- AU$0.75m
- 66
- 15
- 38
- 36
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.91 | ||
| Price to Tang. Book | 7.43 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 64.89 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -38.29% | ||
| Return on Equity | -32.85% | ||
| Operating Margin | -866.27% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 0.01 | 0.1 | 0.51 | 0.34 | 0.75 | n/a | n/a | 153.31% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
INOVIQ Ltd is an Australia-based company. The Company is engaged in developing and commercializing exosome solutions and precision diagnostics to improve the diagnosis and treatment of cancer and other diseases. It operates in one segment, the research and development of cancer diagnostics. The Company has two products in market, which include hTERT ICC test and the EXO-NET Pan-Exosome. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate and other cancers. The hTERT test is an immunocytochemistry (ICC) assay registered for the detection of human telomerase reverse transcriptase (hTERT) in cytopathology samples. It is used as an adjunct to urine cytology to help resolve indeterminate cytology results and identify patients with increased risk of bladder cancer. EXO-NET is a research use only (RUO) pan-exosome capture tool for the isolation of exosomes from body fluids including plasma, urine and saliva.
Directors
- Leearne Hinch CEO
- Irmgard Irminger-Finger CSO
- Greg Rice CSO
- Geoffrey Cumming DRC
- Robert Johnston DRC
- Philip Powell DRC
- Allan Cripps NID
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- June 30th, 1983
- Public Since
- April 18th, 1991
- No. of Shareholders
- 6,045
- No. of Employees
- 85
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 92,018,702
- Address
- 23 Normanby Road, Notting Hill, NEDLANDS, 3168
- Web
- https://www.inoviq.com/
- Phone
- +61 395487586
- Auditors
- Grant Thornton Audit Pty Ltd
Upcoming Events for IIQ
Similar to IIQ
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Algorae Pharmaceuticals
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
FAQ
What is the Inoviq share price?
As of Today at 19:11 UTC, shares in Inoviq are trading at AU$0.53. This share price information is delayed by 15 minutes.
How has the Inoviq share price performed this year?
Shares in Inoviq last closed at AU$0.53 and the price had moved by +12.77% over the past 365 days. In terms of relative price strength the Inoviq share price has outperformed the ASX All Ordinaries Index by +7.86% over the past year.
What are the analyst and broker recommendations for Inoviq?
There is no consensus recommendation for this security.
What is the Inoviq dividend yield?
Inoviq does not currently pay a dividend.
Does Inoviq pay a dividend?
Inoviq does not currently pay a dividend.
When does Inoviq next pay dividends?
Inoviq does not currently pay a dividend.
How do I buy Inoviq shares?
To buy shares in Inoviq you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Inoviq?
As of the previous close price of AU$0.53, shares in Inoviq had a market capitalisation of AU$48.77m.
Where are Inoviq shares listed?
Here are the trading details for Inoviq:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: IIQ
What kind of share is Inoviq?
Based on an overall assessment of its quality, value and momentum Inoviq is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Inoviq share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Inoviq share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Inoviq. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -18.67%.
As of the last closing price of AU$0.53, shares in Inoviq were trading -17.74% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Inoviq PE Ratio?
The Inoviq PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.53.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Inoviq?
Inoviq's management team is headed by:
- Leearne Hinch - CEO
- Irmgard Irminger-Finger - CSO
- Greg Rice - CSO
- Geoffrey Cumming - DRC
- Robert Johnston - DRC
- Philip Powell - DRC
- Allan Cripps - NID